Welcome to our dedicated page for Evolent Health SEC filings (Ticker: EVH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evolent Health, Inc. (NYSE: EVH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K, annual and quarterly reports, and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Evolent’s specialty care business, capital structure, governance and material events affecting the company.
Through its 8-K filings, Evolent reports results of operations and financial condition, such as quarterly earnings releases that include revenue and adjusted EBITDA, explanations of non-GAAP financial measures and management’s discussion of demand for complex specialty care solutions. Other 8-Ks describe capital markets and financing activities, including the issuance of 4.50% convertible senior notes due 2031, the related indenture terms, and the use of proceeds to repurchase 1.50% convertible senior notes due 2025 and shares of Class A common stock. Amendments to credit agreements and commitment letters for incremental facilities are also disclosed, outlining available debt capital and key conditions.
Evolent’s filings further cover strategic transactions, such as the stock purchase agreement to sell its value-based primary care business, Evolent Care Partners, to Privia Management Company, LLC, and subsequent filings noting consummation of that transaction. Governance and leadership changes are documented under Item 5.02 of Form 8-K, detailing appointments and transitions in executive roles, including the Chief Financial Officer, as well as board retirements and new independent director appointments and related compensation and indemnification arrangements.
Regulatory and legal matters appear in filings as well. For example, Evolent has disclosed receiving a Civil Investigative Demand from the Department of Justice in connection with a False Claims Act investigation related to a former customer and Medicare Advantage diagnosis codes, and has stated that it is cooperating with the government.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of earnings releases, financing agreements, strategic transactions, leadership changes and legal disclosures. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, 10-Ks and other forms are available promptly, while structured access to information on insider and executive arrangements can support deeper analysis of Evolent’s corporate governance and compensation practices.
Rubicon Fund II LP and affiliates filed a Schedule 13G on Evolent Health (EVH), reporting beneficial ownership of 5,816,123 shares of Class A Common Stock, or 5.21%, as of November 13, 2025. The holdings are reported through an investment in Puma Growth Holdings, LLC.
The filing lists shared voting and dispositive power over 5,816,123 shares and no sole power. The percentage is based on 111,600,856 shares outstanding as of October 31, 2025, as disclosed by the company. Reporting persons include Rubicon Fund II LP, Rubicon Fund II PF LP, Rubicon Founders OP GP II LP, Rubicon Founders OP GP 2, LLC, Rubicon Founders LLC, and Adam Boehler. Within the group, Rubicon Fund II LP reports 5,032,468.70 shares and Rubicon Fund II PF LP reports 783,654.30 shares.
Evolent Health (EVH): Schedule 13G/A update
Durable Capital Partners LP filed Amendment No. 1 to its Schedule 13G reporting beneficial ownership of 0 shares and 0.0% of Evolent Health’s Class A common stock (CUSIP 30050B101), with the event dated September 30, 2025. The filer notes ownership of five percent or less of the class. The certification states the securities were held in the ordinary course and not for the purpose of changing or influencing control.
Evolent Health (EVH): Schedule 13G/A Amendment No. 2 discloses that Eventide Asset Management and affiliated reporting persons beneficially own 6,292,511 shares of Class A common stock, representing 5.4% of the class as of September 30, 2025.
Eventide reports sole voting and dispositive power over 6,292,511 shares. Finny Kuruvilla, M.D., Ph.D., and Robin C. John report shared voting and dispositive power over 6,292,511 shares. Holdings are allocated across Eventide Gilead Fund (3,900,000; 3.3%), Eventide Healthcare & Life Sciences Fund (2,356,913; 2.0%), Eventide Small Cap ETF (88; 0.0%), and separately managed accounts (35,510; 0.1%). The filing certifies the securities are held in the ordinary course and not for the purpose of changing or influencing control.
Evolent Health (EVH) reported third‑quarter 2025 results with revenue of $479.5 million, down from $621.4 million a year ago. Operating performance improved to a small operating income of $0.9 million versus a prior loss, but the company recorded a net loss of $26.9 million (basic and diluted loss per share $0.24).
On the balance sheet, cash and cash equivalents were $116.7 million and restricted cash was $26.4 million. Long‑term debt rose to $1.05 billion while short‑term debt declined, reflecting refinancing and the exchange of Series A Preferred Stock into a second‑lien term loan; mezzanine equity was removed. The company signed an agreement to sell Evolent Care Partners Holding Company for $100.0 million, plus up to $13.0 million contingent consideration, reclassifying $89.7 million of net assets (including allocated goodwill) to held for sale. For the nine months, operating cash flow was $(10.0) million, influenced by changes in reserves and working capital.
Evolent Health (EVH) filed an 8-K announcing leadership changes and furnishing its Q3 2025 results press release. The release was furnished as Exhibit 99.1.
The Board appointed Mario Ramos as Chief Financial Officer effective January 1, 2026. His compensation includes a $550,000 annual base salary, a maximum cash bonus opportunity of $625,000 under the anticipated 2026 plan, and a $100,000 sign-on bonus. He will receive a one-time RSU grant valued at $2,350,000, vesting 34%/33%/33% on the first three anniversaries of grant, subject to continued employment.
Severance terms provide 12 months of base salary continuation and pro‑rated annual bonus upon a qualifying non‑CIC termination, plus COBRA subsidy for the severance period. Upon a qualifying CIC termination, cash severance equals 1.5x base salary plus target bonus, immediate vesting of time‑based equity, performance equity at the greater of target or actual to date, and COBRA subsidy for up to 18 months. John Johnson will become Chief Strategy Officer on the effective date. Emily Rafferty will move to EVP, Customer Success, and Katie DiPerna will lead non‑clinical operations.
FMR LLC filed an amended Schedule 13G reporting beneficial ownership of 9,416,813.32 shares of Evolent Health (EVH) Class A common stock, representing 8.0% of the class as of 09/30/2025.
FMR reports sole voting power over 9,387,845.20 shares and sole dispositive power over 9,416,813.32 shares. Abigail P. Johnson is listed with sole dispositive power over 9,416,813.32 shares and no voting power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Evolent Health, Inc. reaffirmed its outlook for the three months ending September 30, 2025, guiding Revenue between $460 and $480 million and Adjusted EBITDA between $34 and $42 million. The company also reaffirmed full-year 2025 Revenue guidance of $1.85 to $1.88 billion and Adjusted EBITDA of $140 to $165 million, excluding the impact of a planned divestiture.
Evolent’s subsidiary agreed to sell all shares of Evolent Care Partners Holding Company, Inc. to Privia Management Company, LLC for a purchase price of $100 million, subject to customary adjustments, plus a contingent payment of up to $13 million based on post-closing metrics. Closing is subject to customary conditions, including required state governmental approvals, and is anticipated in the fourth quarter of 2025, after which the company plans to provide updated guidance.
Evolent Health, Inc. filed a Form 8-K disclosing agreements to issue convertible senior notes and related documents. The company entered into an Indenture dated August 21, 2025 with U.S. Bank Trust Company, National Association as trustee and included a form of 4.50% Convertible Senior Notes due 2031 as an exhibit. The filing also lists a Purchase Agreement dated August 18, 2025 with Oppenheimer & Co. Inc. and contains the cover page formatted as Inline XBRL. The report is signed by Jonathan D. Weinberg, General Counsel and Secretary.
Evolent Health, Inc. has priced and increased its offering of 4.50% convertible senior notes due 2031 to $145.0 million, with an option for initial purchasers to buy up to an additional $21.75 million, for a potential total of $166.75 million in notes. The company expects to use about $100.2 million of net proceeds, together with available liquidity, to repurchase approximately $167.4 million principal amount of its existing 1.50% convertible senior notes due 2025 for roughly $167.6 million in cash, effectively refinancing nearer-term debt.
Evolent also plans to use around $40.0 million of the proceeds to repurchase shares of its Class A common stock in privately negotiated transactions at the last reported sale price on August 18, 2025. The new notes and any Class A shares issuable upon conversion will not be registered under the Securities Act and will be sold only under applicable exemptions.